Dow Jones

40,003.59

0.34%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
USOTC
Ligand Pharmaceuticals Incorporated (PK) (LGNZZ)
Ligand Pharmaceuticals Incorporated (PK) (LGNZZ) Noticias

LGNZZ

Ligand Pharmaceuticals (PK) (LGNZZ)

Ligand Pharmaceuticals Incorporated (PK)

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:USOTC:LGNZZ

1

Fecha	Hora	Fuente	Título	Símbolo	Compañía
13/05/2024	17:14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
13/05/2024	16:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
08/05/2024	15:07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
07/05/2024	15:03	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
05/06/2020	15:08	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
08/05/2020	15:29	Edgar (US Regulatory)	Quarterly Report (10-q)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
06/05/2020	15:03	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
24/04/2020	15:10	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
24/04/2020	15:07	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
27/02/2020	16:38	Edgar (US Regulatory)	Annual Report (10-k)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
14/02/2020	12:19	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
14/02/2020	10:34	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
13/02/2020	10:09	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
06/12/2018	15:10	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
24/08/2018	11:41	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
03/07/2018	17:48	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
02/11/2017	05:03	Edgar (US Regulatory)	Amended Quarterly Report (10-q/a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
15/11/2016	05:06	Edgar (US Regulatory)	Amended Annual Report (10-k/a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
09/11/2016	07:31	Edgar (US Regulatory)	Notification That Quarterly Report Will Be Submitted Late (nt 10-q)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
29/07/2016	15:32	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
24/05/2016	12:00	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
25/01/2016	13:39	Edgar (US Regulatory)	Small Company Offering and Sale of Securities Without Registration (d)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)
08/01/2016	15:08	Edgar (US Regulatory)	Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)	USOTC:LGNZZ	Ligand Pharmaceuticals Incorporated (PK)